10.08.26 -- Engineering Better ADCs, Part 1: MoA, Conjugation Chemistry, And More

Listen to Ingrid Ekman on why smoother tech transfer starts much earlier — with systematic data and design of experiments that map a process's boundaries before it ever reaches commercial scale.

By adopting these best practices, biotech sponsors can foster more transparent, efficient, and productive collaborations with their CDMO partners.

Explore a new vision for operations that replaces digital waste with adaptable, worker‑driven tools, as well as how continuous transformation and practical AI frameworks can help teams evolve processes.

See how targeted media supplementation can improve CHO cell culture outcomes, simplify process optimization, and increase productivity across monoclonal antibodies and emerging modalities.

Protect patient safety and ensure regulatory compliance by implementing sensitive, reliable bacterial endotoxin testing as a critical component of pharmaceutical quality assurance.

Solvent selection for spray-dried dispersions significantly impacts drug performance and scalability. Early, structured solvent choice is vital for successful manufacturing and commercialization.

Aseptic drug manufacturing is going small. Discover how advanced robotic and automated systems with smaller footprints are changing the landscape and boosting accessibility.

Evaluate packaging integrity and master wiping techniques to prevent cleanroom contamination. Focus on surface coverage and controlled transfer paths to ensure consistent product safety and quality.

In our series on pre-filled syringes, we examine five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

Build a stronger CCIT strategy with practical guidance on risk assessment, method development, and validation, as well as how to improve collaboration between sponsors and testing laboratories.

Navigate essential biotech and pharma regulations safely. Learn how unifying global standards streamlines audits and accelerates development schedules.

Tailored strategies identify risk early, integrate data-driven insight, and streamline formulation planning to accelerate timelines and position complex molecules for successful development.

As demand for GLP-1s and biologics accelerates and timelines compress, it's become more crucial that companies stay competitive and bring therapies to market faster by partnering with a CDMO.

Reduce development risk and improve readiness for larger trials with strategies that align formulation, manufacturing, and commercialization goals.

Aerosolized hydrogen peroxide decontamination cuts isolator cycle times from 70 to 15 minutes while drastically reducing biocide and overall energy usage.

SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. Read about a model-based framework for managing those risks.

Centralizing data in a unified cloud QMS eliminates manual tracking, enhances operational visibility, and unlocks predictive insights to bring therapies to patients faster.